Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have at least 1 previously untreated superficial basal cell carcinoma tumor~* Minimum tumor size 0.5 cm2 and maximum diameter of 2.0 cm~Exclusion Criteria:~* Evidence of clinically significant, unstable medical conditions~* Cannot have recent use of topical steroids or retinoids in the treatment area.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aldara (Type: EXPERIMENTAL): Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).